Drugs / MRT5005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03375047 | May 2018 → Mar 2022 | cystic fibrosis | Sanofi | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRT5005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03375047 ↗ |
| Route | Inhaled | “MRT5005 administered by nebulization to the respiratory tract” NCT03375047 ↗ |